Paclitaxel Accord Healthcare 6 mg/ml solution à diluer pour perfusion

DRUG2 trials

Sponsors

Institut Bergonie, European Organisation For Research And Treatment Of Cancer

Conditions

Non-small cell lung cancerPatients with locally advanced or metastasic Non-Small Cell Lung Carcinoma.

Phase 2

OPTIMUNE-LUNG : INTEGRATIVE ANALYSIS OF THE TUMOR MICROENVIRONMENT AND OPTIMIZATION OF THE IMMUNOTHERAPY DURATION IN NON-SMALL CELL LUNG CANCER PATIENTS

Active, not recruitingCTIS2023-509490-23-00

Institut BergoniePatients with locally advanced or metastasic Non-Small Cell Lung Carcinoma.

Start: 2021-08-03Target: 80Updated: 2025-05-13

EORTC-2456-LCG-BTG: A randomized phase II study evaluating upfront SRT to all brain metastases followed by ivonescimab plus chemotherapy versus upfront ivonescimab plus chemotherapy in patients with asymptomatic active brain metastases from NSCLC.

Not yet recruitingCTIS2025-522985-60-00

European Organisation For Research And Treatment Of CancerNon-small cell lung cancer

Target: 34Updated: 2026-10-20